ELTX · Elicio Therapeutics, Inc.
$1.89
-0.03 (-1.56%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”View the 10-Q filed Aug 13, 2026
Market Cap
$50.46M
Shares
26.28M
Volume · Oct 5
202.86K
Avg daily vol (3M)
452.52K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.92
Open$1.95
Day$1.85–1.97
52W close$1.77–14.85
Avg vol 30d347K
Short int1.7M · 6.3% float · 4.4d
Short vol65%
Last earningsJun 15, 2026
DataFeb 2021–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-82.7%
Trailing year
Short interest
6.3%
Latest settlement · 4.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−74%
below
Price vs 50-day avg
−25%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−82%
trailing
YTD return
−76%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.34% of float · ▲ +5.2% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
55 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
−92%
Y/Y
EPS growth
+39%
Y/Y
Free cash flow
$-37.0M
Balance sheet
$8.6M
net cash
Quant / Vol
risk profile
Volatility
141%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−74%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+12% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.34% of float · ▲ +5.2% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
55 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 1%
Range high $15
vs 200-day avg -74%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELTX
this stock
Elicio Therapeutics, Inc.
|
$50.46M | -75.9% | -91.9% | — | 6.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELTX | +4.4% | -23.2% | -82.3% | +5.5% | -75.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +4.6% | -22.7% | -94.5% | +4.6% | -88.7% |